Patents by Inventor Mikinaga MORI
Mikinaga MORI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12220482Abstract: An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.Type: GrantFiled: January 4, 2021Date of Patent: February 11, 2025Assignee: FUJIFILM CorporationInventors: Takahiro Sekiguchi, Mikinaga Mori, Kentaro Numajiri, Hiroyuki Kitaoka
-
Publication number: 20240099974Abstract: An object of the present invention is to provide a treatment agent for Merkel cell cancer. According to the present invention, there is provided a treatment agent for Merkel cell cancer, having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, and the inner water phase contains an ammonium salt.Type: ApplicationFiled: November 21, 2023Publication date: March 28, 2024Applicant: FUJIFILM CorporationInventors: Susumu SHIMOYAMA, Mikinaga Mori
-
Publication number: 20240099975Abstract: An object of the present invention is to provide an anti-tumor agent that exhibits a remarkably excellent anti-tumor effect. According to the present invention, there is provided an anti-tumor agent for curing cancer, the anti-tumor agent having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, the inner water phase contains an ammonium salt, and the topotecan or the salt thereof encompassed in the liposome is administered at a dose rate of 0.1 mg/m2 body surface area to 10 mg/m2 body surface area, in terms of topotecan per administration.Type: ApplicationFiled: November 22, 2023Publication date: March 28, 2024Applicant: FUJIFILM CorporationInventors: Susumu SHIMOYAMA, Keiko SUZUKI, Mikinaga MORI, Takeshi MATSUMOTO, Shinji NAKAYAMA, Yasushi MOROHASHI, Toshifumi KIMURA
-
Patent number: 11684575Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.Type: GrantFiled: December 15, 2020Date of Patent: June 27, 2023Assignee: FUJIFILM CorporationInventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
-
Publication number: 20220370352Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.Type: ApplicationFiled: August 5, 2022Publication date: November 24, 2022Applicant: FUJIFILM CorporationInventors: Noriyuki Kasagi, Naoki Yamada, Mikinaga Mori, Takayuki Kato, Takayuki Kobayashi
-
Patent number: 11446247Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.Type: GrantFiled: October 26, 2020Date of Patent: September 20, 2022Assignee: FUJIFILM CorporationInventors: Noriyuki Kasagi, Naoki Yamada, Mikinaga Mori, Takayuki Kato, Takayuki Kobayashi
-
Patent number: 11413244Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.Type: GrantFiled: September 26, 2019Date of Patent: August 16, 2022Assignee: FUJIFILM CorporationInventors: Noriyuki Kasagi, Naoki Yamada, Mikinaga Mori, Takayuki Kato, Takayuki Kobayashi
-
Patent number: 11166914Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.Type: GrantFiled: March 3, 2020Date of Patent: November 9, 2021Assignee: FUJIFILM CorporationInventors: Tsukasa Kitahashi, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
-
Patent number: 11166913Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.Type: GrantFiled: May 1, 2018Date of Patent: November 9, 2021Assignee: FUJIFILM CorporationInventors: Tsukasa Kitahashi, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
-
Patent number: 11154534Abstract: An object of the present invention is to provide a lipid particle composition containing panobinostat or a salt thereof and exhibiting a high bone marrow-targeting capability, and a pharmaceutical composition including the lipid particle composition. According to the present invention, provided is a lipid particle composition containing panobinostat or a salt thereof, in which a lipid particle contains a phospholipid and cholesterol.Type: GrantFiled: June 21, 2019Date of Patent: October 26, 2021Assignee: FUJIFILM CorporationInventors: Yuta Yoshino, Hayato Ogura, Mikinaga Mori, Taisuke Endo, Kentaro Numajiri, Ritsuko Hori
-
Publication number: 20210275453Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.Type: ApplicationFiled: February 25, 2021Publication date: September 9, 2021Applicant: FUJIFILM CorporationInventors: Tsukasa KITAHASHI, Shinji MIMA, Takeshi MATSUMOTO, Takahiro SEKIGUCHI, Mikinaga MORI
-
Publication number: 20210213051Abstract: An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.Type: ApplicationFiled: March 31, 2021Publication date: July 15, 2021Applicant: FUJIFILM CorporationInventors: Ken OKADA, Susumu SHIMOYAMA, Mikinaga MORI
-
Publication number: 20210128471Abstract: An object of the present invention is to provide a liposome composition containing a liposome having an excellent leakage rate of a nucleic acid analog anticancer agent, and a method for producing the same. According to the present invention, there are provided a liposome composition containing a liposome which (1) contains a nucleic acid analog anticancer agent and in which (2) a content ratio of a lysophospholipid contained in a lipid forming the liposome with respect to a total amount of phospholipids other than the lysophospholipid contained in the lipid forming the liposome is 0.01 mol % to 5 mol % and (3) a nucleic acid analog anticancer agent/lipid ratio is 2 mass % to 10 mass %, and a method for producing the same.Type: ApplicationFiled: January 4, 2021Publication date: May 6, 2021Applicant: FUJIFILM CorporationInventors: Takahiro SEKIGUCHI, Mikinaga MORI, Kentaro NUMAJIRI, Hiroyuki KITAOKA
-
Publication number: 20210100745Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.Type: ApplicationFiled: December 15, 2020Publication date: April 8, 2021Applicant: FUJIFILM CorporationInventors: Makoto ONO, Kohei ONO, Takeshi MATSUMOTO, Mikinaga MORI
-
Publication number: 20210100791Abstract: An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition in which liposomes encapsulate a drug with an immune checkpoint inhibitor. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin, and cholesterols, the liposome composition includes a drug and has art inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.Type: ApplicationFiled: December 17, 2020Publication date: April 8, 2021Applicant: FUJIFILM CorporationInventors: Susumu Shimoyama, Tadaaki Ioroi, Mikinaga Mori, Tamami Higuchi
-
Publication number: 20210038518Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.Type: ApplicationFiled: October 26, 2020Publication date: February 11, 2021Applicant: FUJIFILM CorporationInventors: Noriyuki KASAGI, Naoki YAMADA, Mikinaga MORI, Takayuki KATO, Takayuki KOBAYASHI
-
Patent number: 10898435Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.Type: GrantFiled: July 15, 2019Date of Patent: January 26, 2021Assignee: FUJIFILM CorporationInventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
-
Patent number: 10772834Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.Type: GrantFiled: March 30, 2017Date of Patent: September 15, 2020Assignee: FUJIFILM CorporationInventors: Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
-
Publication number: 20200197305Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.Type: ApplicationFiled: March 3, 2020Publication date: June 25, 2020Applicant: FUJIFILM CorporationInventors: Tsukasa KITAHASHI, Shinji Mima, Takeshi Matsumoto, Takahiro Sekiguchi, Mikinaga Mori
-
Publication number: 20200016079Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.Type: ApplicationFiled: September 26, 2019Publication date: January 16, 2020Applicant: FUJIFILM CorporationInventors: Noriyuki KASAGI, Naoki YAMADA, Mikinaga MORI, Takayuki KATO, Takayuki KOBAYASHI